Increased serum levels of sCD163 and CXCL5 correlate not only with autoimmune diseases such as atherosclerosis and rheumatoid arthritis [15-19], but also with adverse events in melanoma patients treated with nivolumab [20]. This evidence concerns the gene CD163 and autoimmune disease.